β actin antibody (Cell Signaling Technology Inc)


Structured Review
β Actin Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin antibody/product/Cell Signaling Technology Inc
Average 97 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
β actin antibody (Cell Signaling Technology Inc)


Structured Review
β Actin Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin antibody/product/Cell Signaling Technology Inc
Average 97 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
β actin (Cell Signaling Technology Inc)


Structured Review

β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Thrombin increases the expression of cholesterol 25-hydroxylase in rat astrocytes after spinal cord injury"
Article Title: Thrombin increases the expression of cholesterol 25-hydroxylase in rat astrocytes after spinal cord injury
Journal: Neural Regeneration Research
doi: 10.4103/1673-5374.357905

Figure Legend Snippet: Cholesterol-25-hydroxylase (CH25H) expression following treatment of astrocytes with thrombin. (A) Primary astrocytes stained with an antibody against glial fibrillary acid protein (GFAP; Alexa Fluor 488-labeled donkey anti-mouse IgG, green) and Hoechst 33342 showing a purity of over 95%. Scale bar: 100 μm. (B) Western blot analysis of CH25H expression following astrocyte stimulation with 1 U/mL thrombin for 24, 48, or 72 hours. Quantities were normalized to β-actin. (C) 3-(4,5)-Dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay of astrocyte viability after stimulation with 0–50 μM argatroban for 24 hours. (D) Western blot analysis of CH25H expression following astrocyte stimulation with 1 U/mL thrombin in the presence or absence of 0–20 μM Argatroban for 24 hours. Quantities were normalized to β-actin. (E) Quantitative polymerase chain reaction analysis of par1 , par3 , and par4 expression in primary astrocytes. Quantities were normalized to gapdh . (F) MTT assay of astrocyte viability after stimulation with 0–5 μM SCH79797 for 24 hours. (G) Western blot analysis of CH25H following astrocyte stimulation with 1 U/mL thrombin in the presence or absence of 0–3 μM SCH79797 for 24 hours. Quantities were normalized to β-actin. Data are expressed as mean ± SEM ( n = 3). * P < 0.05 (one-way analysis of variance followed by Bonferroni’s post hoc comparison test). PAR: Protease-activated receptor; SCH79797: PAR1 inhibitor.
Techniques Used: Expressing, Staining, Labeling, Western Blot, MTT Assay, Real-time Polymerase Chain Reaction

Figure Legend Snippet: Effects of thrombin/protease-activated receptor 1 on the mitogen-activated protein kinase (MAPK)/nuclear factor kappa-B (NFκB) pathway in astrocytes. (A) Western blot analysis of phosphorylated extracellular regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), P38 kinase (P38), and NFκB protein levels following astrocyte stimulation with 0, 0.5, 1, or 2 U/mL thrombin for 24 hours. (B–E) Quantification of phosphorylated ERK, JNK, P38, and NFκB protein levels, normalized to β-actin. (F) Western blot analysis of phosphorylated ERK, JNK, P38, and NFκB protein levels following astrocyte stimulation with 1 U/mL thrombin in the presence of 0–3 μM SCH79797 for 24 hours. (G–J) Quantification of phosphorylated ERK, JNK, P38, and NFκB protein levels, normalized to β-actin. Data are expressed as mean ± SEM ( n = 3). * P < 0.05 (one-way analysis of variance followed by Bonferroni’s post hoc comparison test). SCH79797: Protease-activated receptor 1 inhibitor.
Techniques Used: Western Blot

Figure Legend Snippet: Effects of mitogen-activated protein kinase (MAPK) or nuclear factor kappa-B (NFκB) inhibitors on astrocyte cholesterol-25-hydroxylase (CH25H) expression in response to stimulation with thrombin. (A) Western blot analysis of NFκB expression following treatment with 1 U/mL thrombin in the presence of 10 μM PD98059, 10 μM SP600125, or 10 μM SB203580 for 24 hours. (B) Quantification of NFκB protein expression, normalized to β-actin. (C) Western blot analysis of CH25H expression following treatment with 1 U/mL thrombin in the presence of 10 μM PD98059, 10 μM SP600125, or 10 μM SB203580 for 24 hours. (D) Quantification of CH25H expression, normalized to β-actin. (E) Western blot analysis of CH25H expression following treatment with 1 U/mL thrombin in the presence or absence of 10–100 μM of the NFκB inhibitor PDTC for 24 hours. (F) Quantification of CH25H expression, normalized to β-actin. Data are expressed as mean ± SEM ( n = 3). * P < 0.05 (one-way analysis of variance followed by Bonferroni’s post hoc comparison test). DMSO: Dimethyl sulfoxide; PD98059: extracellular regulated protein kinases inhibitor; SB203580: P38 inhibitor; SP600125: c-Jun N-terminal kinase inhibitor.
Techniques Used: Expressing, Western Blot
mouse anti β actin (Cell Signaling Technology Inc)


Structured Review
Mouse Anti β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti β actin/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
β actin (Cell Signaling Technology Inc)


Structured Review
β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
mouse anti β actin polyclonal antibody (Cell Signaling Technology Inc)


Structured Review
Mouse Anti β Actin Polyclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti β actin polyclonal antibody/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
rabbit beta actin antibody (Cell Signaling Technology Inc)


Structured Review
Rabbit Beta Actin Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit beta actin antibody/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
β actin (Cell Signaling Technology Inc)


Structured Review
β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
β actin (Cell Signaling Technology Inc)


Structured Review

β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "TNFR2 deficiency impairs the growth of mouse colon cancer"
Article Title: TNFR2 deficiency impairs the growth of mouse colon cancer
Journal: International Journal of Biological Sciences
doi: 10.7150/ijbs.72606

Figure Legend Snippet: The deficiency of TNFR2 reduces phosphorylation of AKT and promotes autophagy. (A) Western blot analysis of P-AKT, AKT, and β-actin. The lysates derived from MC38/WT, MC38/TNFR2 -/- #1 (KO #1), MC38/TNFR2 -/- #1 (KO #2); CT26/WT, CT26/TNFR2 -/- #1 (KO #1), and CT26/TNFR2 -/- #2 (KO #2) cells were immunoblotted with a panel of antibodies specific for P-AKT, AKT, and β-actin (a loading control), respectively. The representative figures of the western blot assay were shown. (B) Western blot analysis of LC3, Beclin 1, p62, Atg5, and GAPDH. The lysates derived from MC38/WT, MC38/TNFR2 -/- #1 (KO #1), MC38/TNFR2 -/- #1 (KO #2); CT26/WT, CT26/TNFR2 -/- #1 (KO #1), and CT26/TNFR2 -/- #2 (KO #2) cells were immunoblotted with a panel of antibodies specific for LC3, Beclin 1, p62, Atg5, and GAPDH (a loading control), respectively. The representative figures of the Western blot assay were shown. (C) MC38/WT, MC38/TNFR2 -/- #1, and MC38/TNFR2 -/- #2; CT26/WT, CT26/TNFR2 -/- #1, and CT26/TNFR2 -/- #2 cells were infected with Ad-mCherry-GFP-LC3 at the multiplicity of infection (MOI) = 5, respectively. The mRFP-LC3 and GFP-LC3 puncta were examined by using a confocal microscope. Scale bar =10 μm. The data shown are representatives of at least three separate experiments with similar results.
Techniques Used: Western Blot, Derivative Assay, Infection, Microscopy
anti β actin (Cell Signaling Technology Inc)


Structured Review
Anti β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti β actin/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
β actin (Cell Signaling Technology Inc)


Structured Review

β Actin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Recapitulating thyroid cancer histotypes through engineering embryonic stem cells"
Article Title: Recapitulating thyroid cancer histotypes through engineering embryonic stem cells
Journal: Nature Communications
doi: 10.1038/s41467-023-36922-1

Figure Legend Snippet: A Model of directed differentiation of human embryonic stem cell (hESC) into thyroid lineage. To promote thyroid lineage specification, hESCs were exposed to the indicated stimuli. Treatment with FGF10, KGF, BMP4 and EGF is reported as FKBE. B Cell cycle analysis in non-targeting control (NTC) hESC-derived cells at the indicated stage of thyroid differentiation lineage. The data show percentage of cell number in G0/G1, S, and G2/M cell cycle phases. Data are expressed as mean ± SD of three independent experiments. C Cell proliferation in hESC-derived cells, engineered with the indicated mutations, at the indicated stage of thyroid differentiation lineage, at 7 days. D Invasion analysis in cells engineered as in ( C ) at 72 h. E Clonogenic assay in D22 thyroid progenitor cells (TPCs) engineered as in ( C ) at 21 days. For ( C–E ) statistical significance was calculated using the two-tailed unpaired t test and data are mean ± standard error of three independent experiments. F ( upper panel ) Growth kinetics of xenograft tumors generated by subcutaneous injection of D22 TPCs. ( lower panel ) Frequency of teratocarcinoma (TerC) or TCs obtained by the injection of hESC-derived cells harboring different mutational background, at different stages of thyroid differentiation lineage. Data are shown as mean ± SD. n = 12 mice per group. G H&E staining and immunohistochemistry analysis of thyroglobulin (Tg), cytokeratin 19 (CK19), β-catenin and NIS on xenograft tumors obtained following injection of D22 TPCs engineered with different mutational background and compared with patient-derived PTC, FTC and ATC. Number of tissues analyzed n = 5. Mutational status of human tissues: PTC BRAF mutated ID#6, FTC NRAS mutated, and ATC BRAF/TP53 mutated ID#96. Scale bars, 100 µm. H Correlation analysis in Gene Expression Omnibus (GEO) (GSE33630) of CTNNB1 mRNA expression levels in normal thyroid tissue, PTC and ATC. Boxes represent the interquartile range (IQR) and midline represents the median. Statistical significance was calculated using Kruskal-Wallis test. i Immunoblot analysis of β-catenin in D22 TPCs engineered as in ( c ). β-actin was used as loading control. Source data are provided as a Source Data file.
Techniques Used: Cell Cycle Assay, Derivative Assay, Clonogenic Assay, Two Tailed Test, Generated, Injection, Staining, Immunohistochemistry, Expressing, Western Blot

Figure Legend Snippet: A Heatmap of Wnt-, stemness-, metastasis- and EMT- related genes in D22 TPCs and in D30 mature thyrocytes engineered with the indicated mutations. Data are presented as 2 −ΔCt normalized values of three independent experiments. B Table and Venn diagrams of common (black color) and exclusive upregulated genes (red color) with logFC > 1.5 in D22 TPCs vs thyrocytes (D30). C Immunoblot analysis of TIMP1 and CD44 in hESC-derived cells harboring different mutational background, at D22 and D30. β-actin was used as loading control. One representative of three independent experiments is shown. Source data are provided as a Source Data file. D MMP9 production in cells as in ( C ) at 48 h. Statistical significance was calculated using the unpaired two-tailed t test. Data are expressed as mean ± SD of three independent experiments. E Growth kinetics of xenograft tumors generated by subcutaneous injection of the indicated engineered D22 TPCs and D30 cells overexpressing TIMP1 , MMP9 and CD44 alone and in combination. Data are shown as mean ± SD. n = 10 mice per group. F Relative mRNA expression levels of TIMP1, MMP9 and CD44 in normal ( n = 59) and tumor ( n = 509) thyroid tissue from TGCA database, thyroid carcinoma (THCA) branch. Boxes represent the IQR and midline represents the median. Statistical significance was calculated using the Wilcoxon test. G ( left panel ) Immunohistochemical analysis of TIMP1, CD63, MMP9 and CD44v6 on xenografts obtained by injecting engineered D22 TPCs and compared with normal thyroid tissue, patient-derived PTC, FTC and ATC. Ctrl= negative control. The number of tissues analyzed n = 5. Mutational status of human tissues: PTC BRAF mutated ID#6, FTC NRAS mutated, and ATC BRAF/TP53 mutated ID#96. Scale bars, 100 µm. ( right panel ) Histograms represent the percentage of TIMP1, CD63, MMP9 and CD44v6 positive cells. Data are expressed as mean ± SD of three independent experiments. H CD44v6 flow cytometry analysis (orange histograms) and corresponding isotype-matched control (grey histograms), in engineered D22 TPCs and compared with isolated normal thyroid cells and patient-derived PTC, FTC and ATC cells.
Techniques Used: Western Blot, Derivative Assay, Two Tailed Test, Generated, Injection, Expressing, Immunohistochemical staining, Negative Control, Flow Cytometry, Isolation

Figure Legend Snippet: A Cell proliferation in D22 TPCs engineered with the indicated mutations treated with vehicle, TIMP1, TIMP1 inhibitor (TIMP1i) alone or in combination up to 3 days. B Invasion analysis in D22 TPCs harboring the indicated mutations treated as in ( A ) up to 4 days. For ( A and B ) statistical significance was calculated using the two-tailed unpaired t test and data are mean ± standard error of three independent experiments. C Immunoblot of pAKT and AKT in engineered D22 TPCs treated as in ( A ) for 48 h. β-actin was used as loading control. One representative of three independent experiments is shown. Source data are provided as a Source Data file. D Relative mRNA expression levels of CD44v6 in D22 TPCs engineered with the indicated mutations and treated with TIMP1 inhibitor (TIMP1i) for 24 h. Data are presented as fold change over vehicle ± SD of three independent experiments. E Immunoblot analysis of pAKT and AKT levels in D22 TPCs engineered with the indicated mutations and transduced with control shRNA (scramble, scr) or CD44v6 shRNA (shCD44v6). β-actin was used as loading control. One representative of three independent experiments is shown. Source data are provided as a Source Data file. f Cell proliferation in D22 TPCs engineered with the indicated mutations transduced with control shRNA (scramble, scr) or CD44v6 shRNA (shCD44v6), up to 72 h. G Invasion analysis in D22 TPCs harboring the indicated mutations transduced with control scramble (scr) or shCD44v6, up to 4 days. For ( F and G ) statistical significance was calculated using the two-tailed unpaired t test and data are mean ± standard error of three independent experiments. H Immunoblot analysis of pAKT and AKT in the indicated engineered D22 TPCs overexpressing CD44v6, untreated and treated with TIMP1i for 48 h. β-actin was used as loading control. One representative of three independent experiments is shown. Source data are provided as a Source Data file. I Heatmap of Wnt-, EMT- stemness and metastasis-related genes in D22 TPCs engineered with the indicated mutations and treated with vehicle or TIMP1i for 24 h. Data are presented as normalized 2 −ΔCt values of three independent experiments.
Techniques Used: Two Tailed Test, Western Blot, Expressing, Transduction, shRNA

Figure Legend Snippet: A Relative mRNA expression levels of PAX8, TG, TSHR, TPO and TTF1 in the indicated engineered D22 treated with KISS1R inhibitor (KISS1Ri) alone or in combination with TIMP1 inhibitor (TIMP1i) for 24 h. Data are presented as fold change over vehicle ± SD of three independent experiments. B and c Immunofluorescence analysis of NIS and cell positivity in D22 TPCs engineered with the indicated mutations and treated as in ( A ) for 72 h. Nuclei were counterstained by Toto-3. Statistical significance was calculated using the unpaired two-tailed t test. Scale bars, 20 µm. Data are mean ± SD of 3 independent experiments. n = 12 wells analyzed. D Relative mRNA expression levels of NIS in cells engineered and treated as in ( A ) for 24 h. Data are presented as fold change over vehicle ± SD of three independent experiments. E and F Immunoblot of NIS ( E ) and relative optical density ratio ( F ) in cells as in ( A ) for 48 h. β-actin was used as loading control. One representative of three independent experiments is shown. Source data are provided as a Source Data file. G Radioiodine uptake in the indicated established thyroid cancer cell lines and engineered D22 TPCs treated as in ( A ) for 48 h. For ( F and G ) statistical significance was calculated using the two-tailed unpaired t test and data are mean ± standard error of three independent experiments. H ( left panel ) Growth kinetics of xenograft tumors generated by subcutaneous injection of D22 TPCs engineered for NRAS Q61R /TP53 R248Q treated with TIMP1 inhibitor (TIMP1i) and KISS1R inhibitor (KISS1Ri) alone and in combination. Statistical significance was calculated using the unpaired two-tailed t test. Data are shown as mean ± SD. n = 6 mice per group. ( right panels ) Immunohistochemical analysis of NIS on xenograft tumors obtained following injection of D22 TPCs engineered for NRAS Q61R /TP53 R248Q treated as indicated, left panel . Scale bars, 100 µm. I Kaplan-Meier graph showing the murine survival of D22 TPCs engineered with NRAS Q61R /TP53 R248Q treated as in ( H ). The statistical significance between groups was evaluated using a log rank Mantel-Cox test.
Techniques Used: Expressing, Immunofluorescence, Two Tailed Test, Western Blot, Generated, Injection, Immunohistochemical staining